Bioavailability file: Exemestane

Fabad Journal of Pharmaceutical Sciences

Volumn 32, Issue 2, 2007, Pages 79-89

  Yavuz, Burçin ^a   Bilensoy, Erem ^a   Şumnu, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Aromatase inhibitor; Bioavailability; Breast cancer; Exemestane; Pharmacokinetics

Indexed keywords

EID: 77952894553     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. McPherson K, Steel CM, Dixon JM. Breast cancer: epidemiology, risk factors, and genetics. Br. Med. J 321: 624-628, 2000.
2. Henderson IC, Canellos GP. Cancer of the breast: the past decade (part 1). N. Engl. J. Med 302: 17-30, 1980.
3. Theobald AJ. Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team. Int J Clin Pract 54: 665-669, 2000.
4. Segaloff A. Hormones and mammary carcinogens. In: McGuire WL, editor. Advances in Research and Treatment, Experimental Biology. New York: Plenum Publishing Corp; 1978. p. 1-22.
5. Kirschner MA. The role of hormones in the development of human breast cancer. In: McGuire WL, editor. Breast Cancer 3: Advances in Research and Treatment, Current Topics. New York: Plenum Publishing Corp; 1979. p. 199-226.
6. Santen RJ, Santner S, Davis B, Veldhuis J, Samojilk E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab 47: 1257-1265, 1978. (Pubitemid 9091287)
7. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30, 1995.
8. Lonning PE, Lien EA. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol 21: 158-193, 1995. (Pubitemid 26051651)
9. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 10: 377-384, 1999. (Pubitemid 29236413)
10. Lonning PE. Pharmacology of new aromatase inhibitors. Breast 5: 202-208, 1996.
11. Johannessen DC, Engan T, di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a Phase I study. Clin Cancer Res 3: 1101-1108, 1997.
12. Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D. A predictive model for exemestane pharmacokinetics/ pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol 59(3): 355-364, 2005. (Pubitemid 40388090)
13. ICI Pakistan Limited. Pharmaceutical and Animal Health - Arimidex (online 25.06.02). Available from: URL: http://www.ici.com.pk/html/products/pharma: arimidex.html
14. Lonning PE. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res Treat 49: 45, 1998.
15. Gibson LJ, Bliss J, Massimini G, et al. The Inter-group Exemestane Study (IES): progress of an international breast cancer trial. 1st Milan Breast Cancer Conference 17: 73, 1999.
16. Anon. Phase III randomized study of exemestane versus tamoxifen in postmenopausal women with primary breast cancer who have already received 2-3 years of adjuvant tamoxifen after potentially curable surgery [online]. CancerNet Protocols Database 1998 Sep. Available from: URL: http://cancernet. nci.nih.gov/cgibin/srchcgi.exe
17. Goss PE. Breast cancer prevention - clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 86: 487-493, 2003. (Pubitemid 37412588)
18. FDA NDA 20753/S006 - Approved Labeling.
19. FDA NDA 20753 - Clinical Pharmacology and Biopharmaceutics Review(s).
20. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4: 2089-2093, 1998. (Pubitemid 28415652)
21. Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 111: 377-388, 2008.
22. Scott LJ, Wiseman LR. Exemestane. Drugs 58(4): 675-680, 1999.
23. Clemett D, Lamb HM. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59(6): 1279-1296, 2000. (Pubitemid 30410145)
24. Buzetti F, Barbugian N, Di Salle E, inventors; Farmitalia Carlo Erba, assignee. 6-substituted-androsta-1,4-diene-3,17-diones. US Patent 4,808,616. 1989 Feb 28.
25. Torricelli C, Martini A, Mugetti L, Eli M, DePonti R. Stability studies on steroidal drug/--cyclodextrin kneaded systems. Int J Pharm 75: 147-153, 1991.
26. Lombardi P. Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochimica et Biophysica Acta 1587: 326-337, 2002.
27. Breda M, Pianezzola E, Strolin Benedetti M. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr 620: 225-231, 1993.
28. Allievi C, Zugnoni P, Strolin Benedetti M, Dostert P. Determination of plasma levels of exemestane (FCE 24304) a new irreversible aromatase inhibitor, using liquid chromatography-thermospray mass spectrometry. J. Mass Spectrom 30: 693-697, 1995.
29. Cenacchi V, Baretté S, Cicioni P, Frigerio E, Long J, James J. LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J. Pharm. Biomed. Anal 22: 451-460, 2000.
30. Mareck U, Geyer H, Guddat S, Haenelt N, Kach A, Kohler M, Opfermann G, Thevis M, Schanzer W. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom 20: 1954-1962, 2006.
31. Persiani S, Broutin F, Cicioni P, Stefanini P, Strolin Benedetti M. Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay. Eur J Pharm Sci 4: 331-340, 1996. (Pubitemid 26392429)
32. Yu C, Mao Y, Miao Y, Jiang J. Determination of Exemestane tablet by RP-HPLC. Yaoxue Jinzhan 30(2): 90-92, 2006.
33. Fu X, Wang Z, Yang ZW, Hu JH. The dissolution properties of Exemestane tablets in 3 different mediums. Yaoxue Fuwu Yu Yanjiu 5(1): 54-56, 2005.
34. Li W, Zheng X. Determination of Exemestane and its related compounds in tablets by RP-HPLC. Zhongguo Yaoke Daxue Xuebao 33(6): 537-539, 2002. (Pubitemid 43046436)
35. Yavuz B, Bilensoy E, Şumnu M. Analytical method validation for oral anticancer drug Exemestane. Proceeding of 14th International Pharmaceutical Technology Symposium 191-193, 2008.
36. Wu, J, Wei N, Tian Y. GC detection of residual solvents in Exemestane. Yaowu Fenxi Zazhi 26(2): 244-246, 2006.
37. Jones SA, Jones SE. Exemestane: a novel aromatase inactivator for breast cancer. Clin Breast Cancer 1(3): 211-216, 2000.
38. Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization. J. Biol. Chem 249: 5373-5378, 1974.
39. Brodie AMH, Santen RJ. Aromatase and its inhibitors in breast cancer treatment - overview and perspective. Breast Cancer Res Treat 30: 1, 1994.
40. Brueggemeier RW. Biochemical and molecular aspects of aromatase. J Enzyme Inhibit 4: 101-110, 1990.
41. Di Salle E, Ornati G, Giudici D, Lassus M, Evans TRJ, Coombes RC. Exemestane (FCE 24304) a new steroidal aromatase inhibitor. J Steroid Biochem Mol. Biol 43: 137-143, 1992.
42. Jones S, Vogel C, Arkhipov A. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17: 3418-3425, 1999.
43. Brodie AM, Schwarzel WC, Shaikh AA, Brodie HJ. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3, 17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100: 1684-1695, 1977.
44. Di Salle E, Briatico G, Giudici D, Ornati G, Zaccheo T, Buzzetti F, Nesi M, Panzeri A. Novel aromatase and 5 alphareductase inhibitors. J Steroid Biochem Mol Biol 49: 289-294, 1994.
45. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, Di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 30: 391-394, 1988.
46. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 33: 2933-2942, 1990.
47. Masamura S, Adlercreutz H, Harvey H. Aromatase inhibitor development for the treatment of breast cancer. Breast Cancer Treat 33:19-26, 1995.
48. Cheung KL, Forward D, Jackson L, Robertson J. The combined use of goserelin and anastrozole as second line endocrine therapy in premenopausal women with advanced breast cancer - a study of its clinical and endocrine effects [abstract 1937]. Proc Am Soc Clin Oncol 20: 47b, 2001.
49. Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E, Coombes RC. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52: 5933-5939, 1992.
50. Bajetta E, Zilembo N, Noberasco C, Martinetti A, Mariani L, Ferrari L, Buzzoni R, Greco M, Bartoli C, Spagnoli I, Danesini GM, Artale S, Paolini J. The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur J Cancer 33: 587-591, 1997.
51. Lonning PE. Aromatase inhibition for breast cancer treatment. Acta Oncol 35: 38-43, 1996.
52. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 6: 187-195, 1999. (Pubitemid 29260051)
53. Pharmacia & Upjohn. Aromasin. Exemestane tablets prescribing information. Kalamazoo, Michigan, USA, October 1999.
54. Markopoulos C. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor. Surgical Oncology 17: 113-128, 2008.
55. Semiglazov V. Exemestane (E) vs. tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). J Clin Oncol 23(Suppl. 16): 11S Abstract 530, 2005.
56. Coombes RC, Kilburn LS, Snowdon CF, Intergroup Exemestane Study, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559-570, 2007.
57. Kaufmann M, Bajetta E, Dirix LY. Exemestane is superior to megesterol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of phase III randomized double blind trial. Exemestane Study Group. J Clin Oncol 18: 1399-1411, 2000.
58. Thorne C. Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy. Curr Opin Oncol 19(Suppl): 19-28, 2007.
59. Loibl S, Schwedler K, Von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Clonidine vs. venlafaxine as treatment for hot flashes in breast cancer patients: a double-blind randomized study. J Clin Oncol 23(16): 738, 2005.
60. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23: 259-263, 1996. (Pubitemid 26000605)
61. Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefice S, Buzzoni R, Di Bartolomeo M, Di Leo A, Laffranchi A, Di Salle E. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 72: 1007-1012, 1995.
62. Lonning PE, Bajetta E, Murray R. Activity of Exemestane (Aromasin) in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18: 2234-4224, 2000.
63. Kvinnsland S, Anker G, Dirix L-Y. High activity and tolerability demonstrated for exemestane in postmenopausal women with advanced breast cancer failing tamoxifen. Eur J Cancer 36: 976-982, 2000. (Pubitemid 30316421)
64. Paridaens R, Thomas J, Wildiers J. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 9: 675-683, 1998. (Pubitemid 28495452)
65. Jones S, Belt R, Cooper B. A phase II study of antitumour efficacy and safety of exemestane as a second-line hormonal treatment of postmenopausal patients with metastatic breast cancer refractory to tamoxifen [abstract]. 21st Breast Cancer Symposium; San Antonio (TX) FU 0113, 1998.
66. Paridaens R, Lohrisch L, Dirix L. Exemestane (Aromasin) is highly active and well tolerated as firstline hormonal therapy of metastatic breast cancer (MBC): results of a randomised phase II trial [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans (LA) 316, 2000.
67. Thürlimann B, Paridaens R, Serin D. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 33: 1767-1773, 1997. (Pubitemid 28129201)
68. Lonning PE. Exemestane: a review of its clinical efficacy and safety. Breast 10: 198-208, 2001. (Pubitemid 32529946)
69. Poggesi I, Jannuzzo MG, DiSalle E, Piscitelli G, Rocchetti M, Spinelli R, Broutin F, Ornatti G, Massimini G. Effect of food and formulation on the pharmacokinetics (PK) and pharmacodynamics (PD) of a single oral dose of exemestane (Aromasin, EXE) [abstract 741]. Proc Am Soc Clin Oncol 18: 193a, 1999.
70. Spinelli R, Jannuzzo M, Poggesi I, Frevola L, Broutin F, Cicioni P. Pharmacokinetics (P) of Aromasin1 (Exemestane EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur J Cancer 35(4): 295, 1999.
71. Persiani S, Poggesi I, Cicioni P. Pharmacokinetics of repeated low-doses of exemestane (1,2.5,5 and 10mg) in postmenopausal healthy volunteers. Eur J Cancer 31(5): 198, 1995.
72. Cocchiara G, Allievi C, Berardi A. Urinary metabolism of Exemestane, a new aromatase inhibitor, in rat, dog, monkey and human volunteers. J Endocrinol Invest 17(1): 78, 1994.
73. Di Salle E, Ornati G, Paridaens R, Coombes RC, Lobelle JP, Zurlo MG. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304) In: Motta M, Serio M, editors. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam: Elsevier; 1994. p. 279- 286.
74. Castelli MG, Cocchiara G, Zurlo MG. Excretion balance and absorption of 14C-exemestane in animals and humans. J Endocrinol Invest 17(1): 76, 1994.
75. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881-894, 2001. (Pubitemid 32119104)